EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Adropin promotes glycolytic reprogramming and EMT in pancreatic cancer through β₂-adrenergic receptor/β-arrestin 2/ERK signaling

Jilong Hu, Weibo Wu, Qunhua Ding, Qi Ling, Qiyun Li, Zhinan Zheng

Cellular Oncology · 03.11.2026

DOI: 10.1007/s13402-026-01305-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 03.11.2026. Verfasst von Jilong Hu und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangxi Cancer Hospital Scientific Research Open Fund Project, Science and Technology Research Project of Jiangxi Provincial Education Department.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Jiangxi Cancer Hospital Scientific Research Open Fund Project
  • Science and Technology Research Project of Jiangxi Provincial Education Department

Zitieren

APA

Hu, J., Wu, W., Ding, Q., Ling, Q., Li, Q., & Zheng, Z. (2026). Adropin promotes glycolytic reprogramming and EMT in pancreatic cancer through β₂-adrenergic receptor/β-arrestin 2/ERK signaling. Cellular Oncology. https://doi.org/10.1007/s13402-026-01305-3

Vancouver

Hu J, Wu W, Ding Q, Ling Q, Li Q, Zheng Z. Adropin promotes glycolytic reprogramming and EMT in pancreatic cancer through β₂-adrenergic receptor/β-arrestin 2/ERK signaling. Cellular Oncology. 2026. doi:10.1007/s13402-026-01305-3

BibTeX
@article{Hu2026,
  author = {Hu, Jilong and Wu, Weibo and Ding, Qunhua and Ling, Qi and Li, Qiyun and Zheng, Zhinan},
  title = {Adropin promotes glycolytic reprogramming and EMT in pancreatic cancer through β₂-adrenergic receptor/β-arrestin 2/ERK signaling},
  journal = {Cellular Oncology},
  year = {2026},
  doi = {10.1007/s13402-026-01305-3}
}
Kostenlos starten →